Trial · NCT02478489
Adverse events122
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 122
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Elevated Liver Function Tests | Hepatobiliary disorders | Extended-release Injectable Naltrexone (XR-NTX) | 19 | 123 | |
| other | Elevated Liver Function Tests | Hepatobiliary disorders | Oral Naltrexone (PO-NTX) | 32 | 125 | |
| other | Injection Site Discomfort | Skin and subcutaneous tissue disorders | Extended-release Injectable Naltrexone (XR-NTX) | 36 | 123 | |
| other | Injection Site Discomfort | Skin and subcutaneous tissue disorders | Oral Naltrexone (PO-NTX) | 0 | 0 | |
| other | Intoxication | Injury, poisoning and procedural complications | Extended-release Injectable Naltrexone (XR-NTX) | 16 | 123 | |
| other | Intoxication | Injury, poisoning and procedural complications | Oral Naltrexone (PO-NTX) | 12 | 125 | |
| serious | Abdominal Pain | Gastrointestinal disorders | Extended-release Injectable Naltrexone (XR-NTX) | 1 | 123 | |
| serious | Abdominal Pain | Gastrointestinal disorders | Oral Naltrexone (PO-NTX) | 4 | 125 | |
| serious | Acute Cholecystitis | Hepatobiliary disorders | Extended-release Injectable Naltrexone (XR-NTX) | 0 | 123 | |
| serious | Acute Cholecystitis | Hepatobiliary disorders | Oral Naltrexone (PO-NTX) | 1 | 125 | |
| serious | Alcohol Withdrawal | Psychiatric disorders | Extended-release Injectable Naltrexone (XR-NTX) | 6 | 123 | |
| serious | Alcohol Withdrawal | Psychiatric disorders | Oral Naltrexone (PO-NTX) | 10 | 125 | |
| serious | Altered Mental Status | Nervous system disorders | Extended-release Injectable Naltrexone (XR-NTX) | 1 | 123 | |
| serious | Altered Mental Status | Nervous system disorders | Oral Naltrexone (PO-NTX) | 0 | 125 | |
| serious | Ankle Fracture | Musculoskeletal and connective tissue disorders | Extended-release Injectable Naltrexone (XR-NTX) | 0 | 123 | |
| serious | Ankle Fracture | Musculoskeletal and connective tissue disorders | Oral Naltrexone (PO-NTX) | 2 | 125 | |
| serious | Ankle Pain | Musculoskeletal and connective tissue disorders | Extended-release Injectable Naltrexone (XR-NTX) | 1 | 123 | |
| serious | Ankle Pain | Musculoskeletal and connective tissue disorders | Oral Naltrexone (PO-NTX) | 0 | 125 | |
| serious | Anxiety | Psychiatric disorders | Extended-release Injectable Naltrexone (XR-NTX) | 0 | 123 | |
| serious | Anxiety | Psychiatric disorders | Oral Naltrexone (PO-NTX) | 1 | 125 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02478489/events